Follicular variant of papillary thyroid carcinoma presenting as a toxic nodule by I-123 scintigraphy

Clinical Nuclear Medicine

Volumn 35, Issue 10, 2010, Pages 770-775

  Bommireddipalli, Srinivas ^a   Goel, Sumina ^a   Gadiraju, Ramesh ^a   Paniz Mondolfi, Alberto ^b   Depuey, Ernest Gordon ^b  

^a Division of Medicine   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

follicular variant of papillary thyroid carcinoma; hot nodule; I 123 scintigraphy; PET CT imaging; toxic nodule

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 123; LIOTHYRONINE; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROID HORMONE; THYROTROPIN; THYROXINE;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; ASPIRATION BIOPSY; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CYTOLOGY; DISEASE DURATION; DISEASE SEVERITY; DISTANT METASTASIS; ECHOGRAPHY; FATIGUE; FOLLOW UP; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOTHYROIDISM; LYMPH NODE BIOPSY; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; NECK DISSECTION; NECK TUMOR; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; RECURRENT CANCER; REPEAT PROCEDURE; RETREATMENT; THORAX RADIOGRAPHY; THYROGLOBULIN BLOOD LEVEL; THYROID FOLLICULAR CARCINOMA; THYROID FUNCTION TEST; THYROID NODULE; THYROID PAPILLARY CARCINOMA; THYROID SCINTISCANNING; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; TUMOR ABLATION; TUMOR BIOPSY; WEIGHT REDUCTION; WHOLE BODY SCINTISCANNING;

CARCINOMA, PAPILLARY, FOLLICULAR; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77957376265     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3181e4dc7f     Document Type: Article

References (38)

1. McCaffrey TV. Evaluation of the thyroid nodule. Cancer Control. 2000;7: 223-228.
2. Ragni F, Pinelli D, Facchini M, et al. Thyroid carcinoma in hyperthyroid syndromes [in Italian]. G Chir. 1996;17:158-165.
3. Valenti TM, Macchia E, Pisa R, et al. Toxic adenoma and papillary thyroid carcinoma in a patient with Graves' disease. J Endocrinol Invest. 1999;22: 701-704.
4. Appetecchia M, Ducci M. Hyperfunctioning differentiated thyroid carcinoma. J Endocrinol Invest. 1998;21:189-192.
5. Intenzo CM, Park CH, Cohen SN. Thyroid carcinoma presenting as an autonomous thyroid nodule. Clin Nucl Med. 1990;15:313-314.
6. De Rosa G, Testa A, Maurizi M, et al. Thyroid carcinoma mimicking a toxic adenoma. Eur J Nucl Med. 1990;17:179-184.
7. Calegaro JU, Dias MS, Bae SH, et al. Papillary carcinoma of the thyroid in an autonomously functioning nodule. Arq Bras Endocrinol Metab. 2003;47: 739-743.
8. Rubenfeld S, Wheeler TM. Thyroid cancer presenting as a hot thyroid nodule: report of a case and review of the literature. Thyroidology. 1988;1:63-68.
9. Burguera B, Gharib H. Thyroid incidentalomas. Prevalence, diagnosis, significance and management. Endocronol Metab Clin North Am. 2000;29:187-203.
10. Cakir M, Arici C, Alakus H, et al. Incidental thyroid carcinoma in thyrotoxic patients treated by surgery. Horm Res. 2007;67:96-99.
11. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Taskforce. Thyroid. 2006;16:109-142.
12. Hagag P, Strauss S, Weiss M. Role of ultrasound-guided fine-needle aspiration biopsy in evaluation of nonpalpable thyroid nodules. Thyroid. 1998;8: 989-995.
13. Papini E, Guglielmi R, Bianchini A, et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color Doppler features. J Clin Endocrinol Metab. 2000;87:1941-1946.
14. Hunter R, Oakley JR. Hot nodules of the thyroid gland. Aust N Z J Surg. 1975;45:191-196.
15. Hedinger C, Williams ED, Sobin LH. Histological Typing of Thyroid Tumors. WHO International Histological Classification of Tumors. 4th ed. Berlin, Germany: Springer-Verlag; 1988.
16. Smith M, McHenry C, Jarosz H, et al. Carcinoma of the thyroid in patients with autonomous nodules. Am Surg. 1988;54:448-449.
17. Wenig BM, Heffess CS, Adair CF. Atlas of Endocrine Pathology. Philadelphia, London, Toronto, Montreal, Sydney, Tokyo: WB Saunders Company; 1997.
18. Hawk WA, Hazard JB. The many appearances of papillary carcinoma of the thyroid. Cleve Clin Q. 1976;43:207-216.
19. LiVolsi VA. Well differentiated thyroid carcinoma. Clin Oncol. 1996;8:281-288.
20. Mazzaferri EL, Jhiang S. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;19:418-428.
21. Sobrinho-Simoes M, Spars J, Carneiro F, et al. Diffuse follicular variant of papillary carcinoma of the thyroid: report of eight cases of a distinct aggressive type of thyroid tumor. Surg Pathol. 1990;3:189-203.
22. Guo X, Kleiner D, Fischette M, et al. Aggressive follicular variant of papillary carcinoma [abstract]. Mod Pathol. 1999;12:67A.
23. Tielens ET, Sherman SI, Hurban RH, et al. Follicular variant of papillary thyroid carcinoma: a clinicopathologic study. Cancer. 1994;73:424-431.
24. Chose MK, Genuth SM, Abellera RM, et al. Functioning primary thyroid carcinoma and metastases producing hyperthyroidism. J Clin Endocrinol Metab. 1971;33:639-646.
25. Michigishi T, Mizukami Y, Shuke N, et al. An autonomously functioning thyroid carcinoma with euthyroid Graves' disease. J Nucl Med. 1992;33: 2024-2026.
26. Ikejiri K, Furuyama M, Muranaka T, et al. Carcinoma of the thyroid manifested as hyperthyroidism caused by functional bone metastasis. Clin Nucl Med. 1997;22:227-230.
27. Pandolfi C, Colecchia M, Gianini A. Hyperfunctioning thyroid carcinoma. Description of a case [in Italian]. Minerva Endocrinol. 1997;22:79-82.
28. Gozu H, Avsar M, Bircan R, et al. Does a Leu 512 Arg thyrotropin receptor mutation cause an autonomously functioning papillary carcinoma? Thyroid. 2004;14:975-980.
29. Niepomniszcze H, Suárez H, Pitoia F, et al. Follicular carcinoma presenting as autonomous functioning thyroid nodule and containing an activating mutation of the TSH receptor (T6201) and a mutation of the Ki-RAs (G12C) genes. Thyroid. 2006;16:497-503.
30. Furlan JC, Bedard Y, Rosen IB. Biologic basis for the treatment of microscopic, occult well-differentiated thyroid cancer. Surgery. 2001;130:1050-1054.
31. Sautter-Bihl ML, Herbold G, Heinze HG, et al. Late cervical lymph node recurrence in differentiated thyroid carcinoma. An inherent problem of 131I beta dose distribution in small tumor deposits? Nuklearmedizin. 1992;31: 137-141.
32. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: 10 year follow up report of the impact of therapy in 576 patients. Am J Med. 1981;70:511-518.
33. Pineda JD, Lee T, Ain K, et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab. 1995;80:1488-1492.
34. Alnafisi NS, Driedger AA, Coates G, et al. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma. J Nucl Med. 2000;41: 1010-1015.
35. Schluter B, Bohuslavizki KH, Beyer W, et al. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med. 2001;42:71-76.
36. Choi MY, Chung JK, Lee HY, et al. The clinical impact of 18F-FDG PET in papillary thyroid carcinoma with a negative 131-I whole body scan: a single center study of 108 patients. Ann Nucl Med. 2006;20:547-552.
37. Bloom AD, Adler LP, Shuck JM. Determination of malignancy of thyroid nodules with positron emission tomography. Surgery. 1993;114:728-735.
38. Uematsu H, Sadato N, Ohtsubo T, et al. Fluorine-18-deoxyglucose PET versus thallium 201 scintigraphy evaluation of thyroid tumors. J Nucl Med. 1998;39:453-459.